Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Raze Therapeutics launches with $24mm Series A

Executive Summary

Oncology start-up Raze Therapeutics emerged from stealth mode and raised $24mm through its Series A round. Atlas Venture, MPM Capital Management, and Partners Innovation Fund were joined by venture funds associated with a few major pharmacos as well--Astellas Venture Management (Astellas Pharma Inc.), MS Ventures (Merck Serono SA), and Novartis AG.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies